Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 23;62(3):e01900-17. doi: 10.1128/AAC.01900-17

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Holloway et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

PMC Copyright notice

FIG 5 — rCST9/rCSTC treatment modulated inflammatory responses and preserved lung integrity in a mouse model of pneumonia. BALB/c mice (n = 6 mice/group) were infected i.n. with NDM-1 K. pneumoniae (1.82 × 10⁸ CFU/mouse) and then treated with an i.n. dose of rCST9/rCSTC (50 pg of each/mouse) at 1 h p.i. followed by 500 pg (each) of rCST9/rCSTC per mouse at 3 days p.i. or administered a single i.p. dose of rCST9/rCSTC (500 pg of each/mouse). Sera were collected and lungs, livers, and spleens harvested at 5 days p.i. Fold changes in the overall cytokine levels in the serum (A) and lungs (B) for rCST-treated mice were decreased compared to those for untreated NDM-1 K. pneumoniae-infected mice. Both rCST9/rCSTC treatments modulated cytokine secretion in the serum (C) as well as in all tested organs (D) and significantly reduced the bacterial burden in the lungs (E). (F) Lung histology (H&E staining; magnification, ×40) for the same treated and/or infected mice showed that both rCST treatment regimens minimized lung pathology caused by NDM-1 K. pneumoniae. (G) Further, rCST treatment reduced the number of apoptotic cells compared to that for untreated infected mice. (H) Likewise, MDA detection in the lungs was significantly decreased in rCST-treated infected mice. Graphical data are presented as means and SEM, and asterisks signify significant differences (P < 0.05).

FIG 5 — rCST9/rCSTC treatment modulated inflammatory responses and preserved lung integrity in a mouse model of pneumonia. BALB/c mice (n = 6 mice/group) were infected i.n. with NDM-1 K. pneumoniae (1.82 × 10⁸ CFU/mouse) and then treated with an i.n. dose of rCST9/rCSTC (50 pg of each/mouse) at 1 h p.i. followed by 500 pg (each) of rCST9/rCSTC per mouse at 3 days p.i. or administered a single i.p. dose of rCST9/rCSTC (500 pg of each/mouse). Sera were collected and lungs, livers, and spleens harvested at 5 days p.i. Fold changes in the overall cytokine levels in the serum (A) and lungs (B) for rCST-treated mice were decreased compared to those for untreated NDM-1 K. pneumoniae-infected mice. Both rCST9/rCSTC treatments modulated cytokine secretion in the serum (C) as well as in all tested organs (D) and significantly reduced the bacterial burden in the lungs (E). (F) Lung histology (H&E staining; magnification, ×40) for the same treated and/or infected mice showed that both rCST treatment regimens minimized lung pathology caused by NDM-1 K. pneumoniae. (G) Further, rCST treatment reduced the number of apoptotic cells compared to that for untreated infected mice. (H) Likewise, MDA detection in the lungs was significantly decreased in rCST-treated infected mice. Graphical data are presented as means and SEM, and asterisks signify significant differences (P < 0.05).